This report was first published by Endpoints News. To see the original version, click here
Johnson & Johnson said an experimental eczema medicine didn’t meet its standards for efficacy, ending hopes for a drug that the pharma paid $1.25 billion to get in 2024.
The drug, named JNJ-5939 or NM26, “did not meet the high bar we established for advancing our clinical development programs for atopic dermatitis,” J&J said in a statement on Friday.
您已阅读25%（441字），剩余75%（1312字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。